세계의 예방 의료 시장 예측 : 서비스 유형, 기술, 배포 모드, 용도, 최종 사용자, 지역별 분석(-2032년)

According to Stratistics MRC, the Global Preventive Medicine Market is accounted for $451.59 billion in 2025 and is expected to reach $925.82 billion by 2032 growing at a CAGR of 10.8% during the forecast period. Preventive medicine is a healthcare discipline dedicated to safeguarding, enhancing, and sustaining health by avoiding diseases, injuries, and disabilities before they arise. It includes lifestyle modifications, medical interventions, regular screenings, and immunizations to lower risks and identify potential health problems early. By focusing on proactive care, preventive medicine promotes overall well-being, minimizes healthcare expenses, and supports healthier lives at individual, community, and population scales.

Market Dynamics:

Driver:

Rising Incidence of Chronic Diseases

The growing prevalence of chronic illnesses like heart disease, obesity, and diabetes is fueling demand for preventive healthcare approaches. Since many of these conditions are linked to lifestyle choices, early intervention is increasingly seen as a practical solution to reduce long-term risks. Health systems and policymakers are shifting focus toward prevention to manage costs and improve overall well-being. Awareness campaigns and public education are encouraging individuals to adopt healthier habits and seek regular checkups. Scientific research continues to validate the effectiveness of preventive strategies in lowering disease rates. As a result, chronic disease trends are acting as a major catalyst for the expansion of the preventive medicine industry.

Restraint:

Lack of Aligned Financial Incentives

Preventive care often struggles to gain traction due to misaligned economic incentives within healthcare systems. Many payment structures still prioritize treatment over prevention, making it less attractive for providers to invest in early care models. Physicians may not be rewarded for offering preventive services, which limits their integration into routine practice. Insurance policies frequently exclude coverage for wellness programs and screenings, reducing access for many patients. This cut off between long-term savings and short-term financial returns creates friction in market adoption. Without changes to reimbursement and incentive frameworks, preventive medicine faces challenges in scaling effectively.

Opportunity:

Integration with Digital Health and AI

The fusion of preventive medicine with digital tools and artificial intelligence is opening new avenues for personalized healthcare. Devices like fitness trackers and health apps allow users to monitor their well-being in real time, promoting proactive health management. AI algorithms can analyze data to detect early signs of illness and tailor interventions to individual needs. These technologies also make preventive services more scalable and accessible, especially in areas with limited medical infrastructure. As digital health becomes more widespread, it supports smarter, more efficient approaches to disease prevention. This technological synergy is reshaping how preventive care is delivered and experienced.

Threat:

Data privacy and cybersecurity risks

As preventive medicine increasingly relies on digital platforms, concerns about data security and privacy are becoming more pronounced. Health data collected through apps and remote monitoring systems is susceptible to hacking and unauthorized access. Existing regulations often lag behind the pace of innovation, leaving users exposed to potential misuse. A breach of sensitive information can undermine trust and slow adoption of digital health solutions. Smaller providers may lack the resources to implement strong cybersecurity protocols, increasing vulnerability.

Covid-19 Impact:

The onset of COVID-19 temporarily stalled progress in preventive medicine, as healthcare systems redirected resources to manage the pandemic. Non-urgent services like screenings and wellness visits were delayed, affecting early diagnosis and intervention efforts. However, the crisis underscored the value of proactive health management and system resilience. The rapid adoption of telehealth during lockdowns created new pathways for delivering care remotely. As the world recovers, the pandemic has catalyzed a more prevention-oriented mindset, reinvigorating investment and innovation in the market.

The immunization & vaccination services segment is expected to be the largest during the forecast period

The immunization & vaccination services segment is expected to account for the largest market share during the forecast period, driven by increasing public focus on disease prevention and strengthened global health programs. Vaccine technologies such as mRNA delivery, viral vector systems, and targeted immunology are improving effectiveness and development timelines. Trends like customized immunization, AI-powered logistics, and immuno-informatics are reshaping the landscape. Recent innovations include broad-spectrum flu vaccines, advanced malaria and RSV formulations, and improved supply chain infrastructure. Support from governments and integration with digital platforms are accelerating uptake, positioning vaccines as a cornerstone of modern preventive medicine.

The home healthcare segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the home healthcare segment is predicted to witness the highest growth rate, due to increasing demand for affordable, accessible care amid growing elderly populations and chronic illness rates. Advancements in technology such as smart wearables, virtual consultations, and remote monitoring tools are improving early detection and continuous support. Recent progress includes AI-enabled health tracking, user-friendly mobile platforms, and seamless data integration. Emerging trends emphasize customized care plans, family caregiver engagement, and outcome-based healthcare. This evolution toward proactive, home-based services is reshaping preventive medicine and expanding its reach beyond traditional clinical environments.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by rising lifestyle-related illnesses, demographic shifts, and growing public health consciousness. Innovations in technology such as AI-driven diagnostics, wearable monitoring devices, and digital health platforms are enhancing early intervention and personalized treatment. Recent advancements include app-based wellness tracking, data-driven risk assessments, and scalable preventive care models. Key trends involve expanding telehealth services, employer-sponsored wellness programs, and outcome-focused healthcare delivery. Supportive government policies and increased investment in healthcare infrastructure are propelling the region toward a more preventive and patient-centric approach.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, fuelled by an aging population, rising chronic conditions, and well-established healthcare systems. Advanced technologies such as smart diagnostics, wearable health monitors, and AI-enabled screening are enhancing early intervention and personalized treatment. Notable developments include employer-led wellness initiatives, outcome-based reimbursement models, and expanded insurance coverage for preventive care. Key trends highlight the rise of telemedicine, mobile health solutions, and data-driven risk prediction.

Key players in the market

Some of the key players in Preventive Medicine Market include Novo Nordisk, Medtronic plc, Eli Lilly and Company, Philips Healthcare, Quanterix Corporation, GE HealthCare, U.S. Preventive Medicine, Inc., Siemens Healthineers, Cancer Prevention Pharmaceuticals, Johnson & Johnson, Preventive Medical Health Care, Abbott Laboratories, Phoenix Medicine, F. Hoffmann-La Roche Ltd, Pfizer Inc., Sanofi, and Merck & Co., Inc.

Key Developments:

In July 2025, Eli Lilly and Company announced the successful completion of its acquisition of Verve Therapeutics, Inc., Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. This acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong cardiovascular risk reduction with a one-and-done treatment.

In May 2025, Septerna, Inc. and Novo Nordisk announced an exclusive global collaboration and license agreement to discover, develop and commercialise oral small molecule medicines for obesity, type 2 diabetes and other cardiometabolic diseases. The companies will initially commence four development programmes for potential small molecule therapies directed to one or more select G protein-coupled receptor (GPCR) targets, including the GLP-1, GIP and glucagon receptors.

In April 2025, Medtronic advances Abbott CGM partnership with FDA submission of interoperable insulin pump. Medtronic plc announced it has submitted 510(k) applications to the U.S. Food and Drug Administration (FDA) seeking clearance for an interoperable pump. FDA clearance of this pump would pave the way for system integration with a continuous glucose monitoring (CGM) sensor based on Abbott's most advanced CGM platform.

Service Types Covered:

• Health Screenings & Risk Assessments
• Immunization & Vaccination Services
• Lifestyle & Wellness Programs
• Genetic Testing & Personalized Medicine
• Digital Preventive Solutions
• Other Service Types

Technologies Covered:

• Early Detection & Screening Technologies
• Remote Monitoring Devices
• Chronic Disease Management Platforms
• Predictive Analytics & AI Tools

Mode of Deliveries Covered:

• In-Person Services
• Telemedicine & Remote Care Services
• Mobile Health Applications

Applications Covered:

• Cardiovascular Diseases
• Cancer
• Diabetes
• Infectious Diseases
• Respiratory Diseases
• Neurological Disorders
• Other Applications

End Users Covered:

• Hospitals & Clinics
• Diagnostic Centers
• Corporate & Workplace Wellness Providers
• Home Healthcare
• Government & Public Health Agencies
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Technology Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Preventive Medicine Market, By Service Type

• 5.1 Introduction
• 5.2 Health Screenings & Risk Assessments
• 5.3 Immunization & Vaccination Services
• 5.4 Lifestyle & Wellness Programs
• 5.5 Genetic Testing & Personalized Medicine
• 5.6 Digital Preventive Solutions
• 5.7 Other Service Types

6 Global Preventive Medicine Market, By Technology

• 6.1 Introduction
• 6.2 Early Detection & Screening Technologies
• 6.3 Remote Monitoring Devices
• 6.4 Chronic Disease Management Platforms
• 6.5 Predictive Analytics & AI Tools

7 Global Preventive Medicine Market, By Mode of Delivery

• 7.1 Introduction
• 7.2 In-Person Services
• 7.3 Telemedicine & Remote Care Services
• 7.4 Mobile Health Applications

8 Global Preventive Medicine Market, By Application

• 8.1 Introduction
• 8.2 Cardiovascular Diseases
• 8.3 Cancer
• 8.4 Diabetes
• 8.5 Infectious Diseases
• 8.6 Respiratory Diseases
• 8.7 Neurological Disorders
• 8.8 Other Applications

9 Global Preventive Medicine Market, By End User

• 9.1 Introduction
• 9.2 Hospitals & Clinics
• 9.3 Diagnostic Centers
• 9.4 Corporate & Workplace Wellness Providers
• 9.5 Home Healthcare
• 9.6 Government & Public Health Agencies
• 9.7 Other End Users

10 Global Preventive Medicine Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Novo Nordisk
• 12.2 Medtronic plc
• 12.3 Eli Lilly and Company
• 12.4 Philips Healthcare
• 12.5 Quanterix Corporation
• 12.6 GE HealthCare
• 12.7 U.S. Preventive Medicine, Inc.
• 12.8 Siemens Healthineers
• 12.9 Cancer Prevention Pharmaceuticals
• 12.10 Johnson & Johnson
• 12.11 Preventive Medical Health Care
• 12.12 Abbott Laboratories
• 12.13 Phoenix Medicine
• 12.14 F. Hoffmann-La Roche Ltd
• 12.15 Pfizer Inc.
• 12.16 Sanofi
• 12.17 Merck & Co., Inc.